Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

IHC Testing Aims to Expand Personalized Treatment in Lung Cancer

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and…

As part of the Patient Academy of the Fulda Clinic, the Fulda Clinic is inviting visitors to an information event on lung cancer on 14 May 2025 from 16.30 to 6 p.m. on the campus floor (5th floor INO Center). Lung cancer is one of the most common cancers in Germany and occurs in women and men alike. However, lung cancer is often only (too) detected late, as it rarely causes symptoms in the early stages. However, there are good chances of healing…

Lung Cancer Screening Saves Lives

If you are a current or former smoker, you may qualify for a 10-minute lifesaving screening In 2023, one in eight adults was a smoker in Rockland County. Lung cancer is the most common cancer in Rockland County and is the leading cause of death from cancer nationwide. According to the Lung Cancer Research Foundation, an estimated 226,650 people will be diagnosed with lung cancer in 2025 in the United States. One in 16 people will be diagnosed wi…